Illustrative image – not actual.
Drug maker Lupin has received USD 25 million (around Rs 205 crore) from AbbVie for achieving a key milestone for a product which can treat hematological cancers.
The achievement is in the area of Phase-I clinical studies for its novel Mucosa-Associated Lymphoid Tissue Lymphoma Translocation Protein-1 (MALT-1) inhibitor program. In 2018, Lupin and AbbVie had inked an agreement for the licensing, development, and commercialisation for the novel oncology drug.
The pharmaceutical company’s novel drug discovery and development (NDDD) team is focused on building innovative new chemical entities in this space, as it steps up development of the significant treatment.
The drug maker had earlier received USD 30 million from AbbVie for reaching other milestones in the programme.
